Form 4: Moderna's Chief Legal Officer Reports Stock Transactions

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reports the vesting and conversion of restricted stock units into common stock, along with related tax withholding transactions.

Summary

• On February 27, 2025, Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., engaged in transactions involving Moderna's common stock and restricted stock units.
• Klinger converted 3,094 restricted stock units into common stock and acquired an additional 2,653 shares through restricted stock unit conversions.
• Simultaneously, Klinger disposed of 1,496 and 1,283 shares of common stock, respectively, to cover tax withholding obligations at a price of $33.58 per share.
• Following these transactions, Klinger directly owns 24,735 shares of Moderna common stock and 9,283 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common for publicly traded companies like Moderna. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The transactions reported are typical for executives who receive stock-based compensation.
• Similar filings are made by executives at companies like Pfizer, BioNTech, and Johnson & Johnson when they trade their company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent routine stock activity by an executive.
• The filing provides transparency to shareholders regarding insider transactions.

Key Dates